Reproduce with confidence
Establish the laboratory, software, quality and supply systems around the assigned technology and workflow.
Company
We went looking for a better way
and found a technology already in practice
Fidelion was created around a search for technology that could add molecular continuity after cancer treatment. That search led to VitaGuard—a functioning tumour-naive MRD workflow with commercial operating experience.
How Fidelion began
A need led to a search
and the search led to VitaGuard
Cancer follow-up is often built around isolated moments. The Fidelion team went looking for an approach that could add molecular continuity after treatment.
It found VitaGuard: a functioning tumour-naive MRD workflow with commercial operating experience. Fidelion now holds assigned international development and commercialisation rights outside Greater China and is undertaking the transfer, validation, quality and access work required for new markets.
Why we brought it forward
Give cancer follow-up
another way to see change
VitaGuard could add molecular context between the established moments of care—and, over time, create richer histories for reporting, research and carefully validated analytics.
See the larger opportunity →International development
Establish the workflow, validate its use
and build access responsibly
Fidelion’s programme brings together laboratory implementation, performance studies, quality systems and qualified partners for new markets.
Establish performance
Begin with colorectal cancer MRD and establish performance for each intended population and setting.
Reach through partners
Work with laboratories, health systems and regional leaders to build responsible routes to patients.
Learn responsibly
Develop reporting, research and analytics only where consent, rights and evidence support them.
What Fidelion brings
A test becomes more valuable
when the right system grows around it
From sample preparation and sequencing to bioinformatics, reporting, quality and supply.
Analytical validation, clinical studies and evidence relevant to each population and use.
Structured longitudinal reporting and relationships across clinical care, laboratories and biopharma.
Leadership
Science, capital markets
and cross-border execution
The core team brings together technical development, financing and international partner execution.
Sam Tan
Capital markets and global biotechnology.
Dr Yan Linghua
Founder and CEO of Tongshu Gene; molecular diagnostics and clinical genomics.
Dr Muthu Meyyappan
International commercialisation and partnerships.
Corporate structure
Clear roles support
accountable execution
Fidelion combines technology originating in Tongshu’s molecular-diagnostics programme, assigned international rights outside Greater China and a Southeast Asian licensing relationship with BioNexus Gene Lab Corp.
Fidelion and BioNexus are separate legal entities. BioNexus is a minority shareholder in Fidelion and its exclusive VitaGuard licensee for Southeast Asia. Read the corporate relationship disclosure.
How we think about governance →